Aurora Cannabis Inc. announced its financial and operational results for the fourth quarter and full fiscal year 2025, ending March 31, 2025. The company reported an exceptional year, highlighted by record annual global medical net revenue, adjusted EBITDA, and positive free cash flow.
For Q4 2025, total net revenue increased 34% year-over-year to $90.5 million. Medical cannabis net revenue grew 48% to $67.8 million, representing 75% of consolidated net revenue, with international revenue more than doubling and accounting for 61% of global medical cannabis net revenue.
Adjusted EBITDA for Q4 2025 increased 619% to $16.7 million, and the company generated positive free cash flow of $2.5 million, marking its third consecutive quarter of positive free cash flow. These results underscore the thoughtful execution of Aurora's strategic plan and strengthen its foundation for sustained and profitable growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.